A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

The study will assess how ARGX‐121 affects immunoglobulin A nephropathy (IgAN) diseaseoutcomes, such as renal function, how it is distributed and eliminated from the body, andhow the immune system responds in adults with IgAN.While in the study, participants will continue to receive their usual medical care andmedications for IgA nephropathy, unless the study doctor confirms otherwise.The study will include a double blinded period, followed by an active drug period, andconclude with a follow up period. The total study duration for participants will beapproximately 72 weeks, with a maximum of 52 weeks on ARGX‐121.